{"brief_title": "A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma", "brief_summary": "To evaluate the response rate, response duration, and survival of patients treated with CC-5013 in a chronic dosing schedule versus a syncopated dosing schedule.", "condition": "Multiple Myeloma", "intervention_type": "Drug", "intervention_name": "CC-5013", "criteria": "- History of histologically documented multiple myeloma with relapsed or resistant disease - Pregnant or nursing women may not participate. Women of childbearing potential must have a negative pregnancy documented within one week of registration. Women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method. - Signed written informed consent and willingness to meet follow-up schedule and study procedure obligations", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00051116.xml"}